Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Seagen Inc

Global Pharma Has $700B For M&A And Investments – From AI To Obesity Drugs

Goldman Sachs research suggests the global pharmaceutical sector has approximately $700 billion available for M&A and investments

Pfizer to pay $43 billion for Seagen, set post-COVID course

Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma.

Tribune News Service

Pfizer to buy cancer drugmaker Seagen in $43 billion deal

Pfizer Inc. agreed to purchase cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, gaining the company’s antibody drugs that fight tumors.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price. Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent…

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

Merck & Co Inc (NYSE:MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported, citing people familiar with the matter. The Journal mentioned that the deal could be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to…

SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know

SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).

Merck Shows Takeover Interest In Seagen: WSJ

Merck & Co Inc (NYSE:MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a…

inkl

Read news from The Economist, FT, and more,
with one subscription

HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications

HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications

ADC Therapeutics SA (NYSE:ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301) in relapsed or refractory Hodgkin lymphoma. Cami demonstrated a 70.1% overall response rate (ORR), with a 33.3% complete response (CR) rate. From a safety perspective, eight of 117 patients developed Guillain-Barré syndrome…

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer

Seagen Inc (NASDAQ:SGEN) announced topline results from phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in combination with trastuzumab in previously treated HER2-positive metastatic colorectal cancer (mCRC) patients. Trastuzumab is sold under the name Herceptin by Genentech, a unit of Roche Holdings AG (OTC:RHHBY). Data from this trial will form the basis of a planned supplemental…

Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence

Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence

The Board of Directors of Seagen Inc (NASDAQ:SGEN) announced that its long-time president, CEO, and chairman Clay Siegall, is on a leave of absence. The move follows an alleged incident of domestic violence. While Siegall, who informed the company that he's in the middle of a divorce, denied those allegations. The Seagen board…

Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales

Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales

Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets

Sanofi SA (NASDAQ:SNY) and Seagen Inc (NASDAQ:SGEN) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing…

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF)

Why Are Seagen Shares Sinking Today?

Why Are Seagen Shares Sinking Today?

Seagen Inc (NASDAQ: SGEN) reported Q4 revenues

Get all your
news in one place.

100’s of premium titles.
One news app.

Seagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer

Seagen Inc (NASDAQ: SGEN)

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Wall Street Journal

Cantor Fitzgerald

Board of Directors

RBC Capital Markets

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

domestic violence

Places

323,318 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play